Figure 4.

Myxoma Oncolytic Gene-Editing Viral Therapy Significantly Reduces ERMS Tumor Growth

(A) Schematic of the engineered gene-editing oncolytic MYXV and NRAS-targeting strategy with gRNA target sites (red arrows). (B) Phase and GFP fluorescent images showing recombinant MYXV-infected areas in ERMS tumors (scale bar: 1 mm). (C) High-efficiency gDNA deletions detected at the safe harbor (control virus) and NRAS target sites in representative MYXV-treated ERMS tumors. Sequencing of the most common NRAS deletion mutation is shown. (D) Mouse survival over time compared between NRAS-targeted (blue), safe-harbor-targeted (red), and wild-type uninfected ERMS tumors (n = 6, n = 6, and n = 20, respectively). Tumor growth over time (E) and change in tumor volume (3 weeks) (F) for NRAS- and safe-harbor-targeted tumors. Error bars represent mean ± SD. *p < 0.05.